The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.